Leadership

Emily S. Arcamone, B.S., RLATG

Business Development Account Manager, External Alliance Project Coordinator

Emily joined the team in 2013. As Business Development Account Manager and External Alliance Project Coordinator, she develops proposals and assist with the execution of contracts and service agreements. To accomplish that she works with scientific project leaders and project management staff to establish and initiate new study proposals. She interacts with cross-functional scientific directors through the strategic planning and delivery of the development program, proactively identifying and managing issues in order to ensure satisfactory turn-around-time to all incoming projects.



Emily has over 20 years of experience working in the biotechnology field, including over 15 years in a management role. She joined Invivotek’s management team as a Resource Coordination Manager from Taconic Biosciences, where she had a similar title. Emily has extensive experience in the planning, scheduling, and allocation of resources to maximize the efficiency of the team including in vivo and in vitro Research Associates
Emily received her B.S. in Animal Sciences from Rutgers University.

Emily joined the GGG team in 2013. As Business Development Account Manager and External Alliance Project Coordinator, she develops proposals and assist with the execution of contracts and service agreements. To accomplish that she works with scientific project leaders and project management staff to establish and initiate new study proposals. She interacts with cross-functional scientific directors through the strategic planning and delivery of the development program, proactively identifying and managing issues in order to ensure satisfactory turn-around-time to all incoming projects.



Emily has over 20 years of experience working in the biotechnology field, including over 15 years in a management role. She joined Invivotek’s management team as a Resource Coordination Manager from Taconic Biosciences, where she had a similar title. Emily has extensive experience in the planning, scheduling, and allocation of resources to maximize the efficiency of the team including in vivo and in vitro Research Associates
Emily received her B.S. in Animal Sciences from Rutgers University.

Graham Fletcher, Ph.D.

Chief Operating Officer, Disease Modeling Division

Dr. Fletcher joined the team in 2024. As Chief Operating Officer of the Disease Modeling Division of GD³, he provides leadership, oversight, and coordination for developing and managing operational components, including IACUC and GLP compliance activities and internal study scheduling. He works closely with clients and the Business Development team to understand their needs, design projects, and oversee their studies.

Dr. Fletcher is an accomplished preclinical and clinical drug development scientist and pharmacologist who has held senior roles in small molecule and therapeutic antibody programs. He brought to the team over 20 years of experience covering the drug development process from target discovery and validation through Phase I/II clinical trials with particular therapeutic expertise in Oncology and Immuno-oncology (IO). Dr. Fletcher has extensive experience in team and project management, leading multidisciplinary teams to take three oncology drugs from candidate selection through IND development into nine clinical trials. He deeply understands the drug development process and oncology and IO, encompassing biological, translational, and clinical science. He previously held positions with EntreMed Inc. as a Research Scientist III, Campbell Family Institute, within the University Health Network, Toronto and Treadwell Therapeutics as Head of Preclinical Development, and Medicenna Therapeutics as Director of Clinical Science.

Dr. Fletcher received a BSc in Molecular Biology at Edinburgh University in Edinburgh, Scotland. He earned a Ph.D. in Cell Biology from the University of Cambridge in Cambridge, United Kingdom. Dr. Fletcher is an author of over 20 publications and patents.

Dr. Fletcher joined the team in 2024. As Chief Operating Officer of the Disease Modeling Division of GD3, he provides leadership, oversight, and coordination for developing and managing operational components, including IACUC and GLP compliance activities and internal study scheduling. He works closely with clients and the Business Development team to understand their needs, design projects, and oversee their studies.

Dr. Fletcher is an accomplished preclinical and clinical drug development scientist and pharmacologist who has held senior roles in small molecule and therapeutic antibody programs. He brought to the team over 20 years of experience covering the drug development process from target discovery and validation through Phase I/II clinical trials with particular therapeutic expertise in Oncology and Immuno-oncology (IO). Dr. Fletcher has extensive experience in team and project management, leading multidisciplinary teams to take three oncology drugs from candidate selection through IND development into nine clinical trials. He deeply understands the drug development process and oncology and IO, encompassing biological, translational, and clinical science. He previously held positions with EntreMed Inc. as a Research Scientist III, Campbell Family Institute, within the University Health Network, Toronto and Treadwell Therapeutics as Head of Preclinical Development, and Medicenna Therapeutics as Director of Clinical Science.

Dr. Fletcher received a BSc in Molecular Biology at Edinburgh University in Edinburgh, Scotland. He earned a Ph.D. in Cell Biology from the University of Cambridge in Cambridge, United Kingdom. Dr. Fletcher is an author of over 20 publications and patents.